

<b>Interview Summary</b>	Application No.	Applicant(s)	
	10/540,840	MORIMOTO ET AL.	
	Examiner MELISSA S. MERCIER	Art Unit 1615	

All participants (applicant, applicant's representative, PTO personnel):

(1) MELISSA S. MERCIER. (3)N/A.

(2) Jennifer Hayes. (4)N/A.

Date of Interview: 08 January 2009.

Type: a) Telephonic b) Video Conference  
c) Personal [copy given to: 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.

If Yes, brief description: \_\_\_\_\_.

Claim(s) discussed: N/A.

Identification of prior art discussed: Omori (JP 2004179426).

Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Ms. Hayes stated she had not received and was unable to locate a copy of the cited art. A copy was faxed to her per her requested..

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

/Melissa S Mercier/ Examiner, Art Unit 1615	
--	--



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

# Fax Cover Sheet

Date: 08 Jan 2009

To: Jennifer Hayes	From: Melissa Mercier
Application/Control Number: 10/540840	Art Unit: 1615
Fax No.: 202-293-7860	Phone No.: 571-272-9039
Voice No.: 202-775-7533	Return Fax No.:
Re: Omori Reference	CC:
<input type="checkbox"/> Urgent <input type="checkbox"/> For Review <input type="checkbox"/> For Comment <input type="checkbox"/> For Reply <input checked="" type="checkbox"/> Per Your Request	

Comments:

Attached is the Omori Abstract per your requested.

Number of pages 2 including this page

#### STATEMENT OF CONFIDENTIALITY

This facsimile transmission is an Official U.S. Government document which may contain information which is privileged and confidential. It is intended only for use of the recipient named above. If you are not the intended recipient, any dissemination, distribution or copying of this document is strictly prohibited. If this document is received in error, you are requested to immediately notify the sender at the above indicated telephone number and return the entire document in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

**PAT-NO:** JP02004149426A  
**DOCUMENT-** JP 2004149426 A  
**IDENTIFIER:**  
**TITLE:** L-CYSTEINE-CONTAINING SOLID PHARMACEUTICAL  
PREPARATION AND METHOD FOR STABILIZING THE SAME  
**PUBN-DATE:** May 27, 2004

**INVENTOR-INFORMATION:**

<b>NAME</b>	<b>COUNTRY</b>
OMORI, SHINJI	N/A
ONO, YASUO	N/A
MAKINO, TADASHI	N/A

**ASSIGNEE-INFORMATION:**

<b>NAME</b>	<b>COUNTRY</b>
TAKEDA CHEM IND LTD	N/A

**APPL-NO:** JP2002313977

**APPL-DATE:** October 29, 2002

**INT-CL** A61K047/18 , A61K009/28 , A61K031/375 , A61K031/4188 ,  
**(IPC)** A61K031/4415 , A61K031/455 , A61K031/519

**ABSTRACT:**

**PROBLEM TO BE SOLVED:** To provide a solid pharmaceutical preparation comprising L-cysteine formulated therein and having effects on alleviation of dermal stains, ephelides, skin roughening, acne vulgaris, etc.

**SOLUTION:** The stability of the L-cysteine-containing solid pharmaceutical preparation is improved by blending the L-cysteine therein without using a raw material derived from an animal as the L-cysteine.

**COPYRIGHT:** (C)2004, JPO